ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Neurology · Cephalalgia · 2025-11-18

In adults with episodic migraine and inadequate response to 2-4 oral preventive classes, rimegepant 75 mg every other day cut monthly migraine days more than placebo over 12 weeks (-2.1 vs -0.5; difference -1.6 days); tolerability was similar to placebo.

RCTn = 652
Pozo-Rosich et al. A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.